August 28, 2019 / 6:37 AM / 18 days ago

U.S. FDA grants orphan drug status to AstraZeneca's asthma drug Fasenra

Aug 28 (Reuters) - AstraZeneca said on Wednesday that the U.S. Food and Drug Administration has granted orphan drug status to its severe asthma drug, Fasenra, to treat eosinophilic oesophagitis (EoE).

EoE, also known as allergic oesophagitis, is an allergic inflammation of the esophagus that involves a form of white blood cell, eosinophils.

AstraZeneca also separately said it met the main goal for its late-stage ETHOS trial for triple-drug therapy Breztri Aerosphere, formerly known as PT010, to treat moderate to very severe chronic obstructive pulmonary disease (COPD). (Reporting by Justin George Varghese in Bengaluru; Editing by Bernard Orr)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below